SYS-CON MEDIA Authors: Mat Mathews, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

Global Chiral Technology Market Report

DUBLIN, April 11, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/zxblrf/global_chiral) has announced the addition of the "Global Chiral Technology Market Report" report to their offering. 
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The analysts forecast the Global Chiral Technology market to grow at a CAGR of 14.53 percent over the period 2013-2017. One of the key factors contributing to this market growth is the favorable governmental regulations. The Global Chiral Technology market has also been witnessing the increasing outsourcing of pharmaceutical production to the APAC Region. However, the complexity of chiral chemistry could pose a challenge to the growth of this market. 

The report, the Global Chiral Technology Market 2013-2017, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, APAC region; it also covers the Global Chiral Technology market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Many global pharmaceutical companies are nowadays facing several challenges such as patent expirations and pricing pressures. As a result, these companies are on the lookout for cost containment measures. For instance, drug manufacturing in Asian countries is less expensive than it is in western countries. Further, the growing prominence of Asia as an end-user market and its growth in terms of manufacturing as well as human resource capabilities is expected to contribute to the growth of the market during the forecast period.

According to the report, governmental regulations that support the use of chiral technology constitute a major driver in this market. Healthcare authorities in many countries have introduced guidelines and policies that provide incentives for investments made in developing single enantiomer drugs. 

Further, the report states that one of the main challenges in this market is the complexity of chiral chemistry. The complexity of chiral chemistry is higher in the case of molecules containing multiple chiral centers. As a result, the selection of an appropriate technique for the synthesis and resolution of such molecules becomes challenging.

The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Bachem Holding AG, Cambrex Corp., Codexis Inc, Johnson Matthey plc, Novasep Inc., Phenomenex Inc., Regis Technologies Inc., Solvias AG, and Strem Chemicals Inc.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. 


Key Topics Covered: 

1. Executive Summary

2. Scope of the Report

3. Market Research Methodology

4. List of Abbreviations

5. Introduction

6. Market Landscape

7. Market Segmentation by Technology

8. Geographical Segmentation

9. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

17. Key Vendor Analysis

18. Other Reports in this Series 


Companies Mentioned:

  • BASF SE
  • Bachem Holding AG
  • Cambrex Corp.
  • Codexis Inc.
  • Daicel Corp.
  • Johnson Matthey plc
  • Novasep Inc.
  • Phenomenex Inc.
  • Regis Technologies Inc.
  • Royal DSM N.V.
  • Solvias AG
  • Strem Chemicals Inc..



For more information visit http://www.researchandmarkets.com/research/zxblrf/global_chiral


Media Contact: Laura Wood , +353-1-481-1716, [email protected]


SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.